Oxra 10 Mg (Dapagliflozin) – Product Overview

Oxra 10 Mg is a prescription oral medication that belongs to the class of sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors. It is manufactured by Sun Pharmaceutical Industries Ltd and is formulated for the management of type 2 diabetes mellitus. Each strip contains 14 tablets, each delivering 10 mg of dapagliflozin, a compound that helps the kidneys filter excess glucose from the bloodstream.

What Is Oxra 10 Mg?

Oxra 10 Mg contains the active ingredient dapagliflozin, a selective inhibitor of the SGLT‑2 (NIH) protein located in the proximal renal tubule. By blocking this transporter, the drug reduces glucose reabsorption, leading to lower post‑prandial glucose levels and improved glycemic control in adults with type 2 diabetes. The medication is not intended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

Uses and Benefits

The primary indication for Oxra 10 Mg is to improve glycemic control alongside diet and exercise in adults with type 2 diabetes. Clinical studies have demonstrated that treatment with dapagliflozin can lower HbA1c by approximately 0.5 % to 1.0 % on average. In addition to glucose lowering, the drug has been associated with modest reductions in body weight and systolic blood pressure, which can contribute to cardiovascular risk reduction in high‑risk patients.

In addition to improving glycemic control, clinical data suggest that Oxra 10 Mg can produce modest reductions in systolic blood pressure and promote modest weight loss. These effects are thought to arise from the drug’s natriuretic action and its ability to increase urinary calorie loss. Patients often experience a small but measurable decrease in body mass index over several months, which may contribute to a lower long‑term risk of cardiovascular events in individuals with type 2 diabetes who have additional risk factors such as hypertension or dyslipidemia.

How It Works

Dapagliflozin acts by selectively inhibiting the SGLT‑2 (NIH) transporter in the renal proximal tubule. Under normal physiological conditions, this transporter reabsorbs filtered glucose back into the bloodstream. When SGLT‑2 is blocked, excess glucose is excreted in the urine, resulting in a caloric loss that can modestly aid weight management. The resulting natriuresis (increased sodium excretion) also contributes to a slight reduction in blood pressure.

Pharmacokinetically, dapagliflozin is absorbed rapidly after oral administration, reaching peak plasma concentrations within one to two hours. The drug undergoes minimal hepatic metabolism and is eliminated primarily unchanged through the kidneys, resulting in a half‑life of approximately 13 hours that supports once‑daily dosing. Because elimination occurs via renal excretion, co‑administration with medications that affect renal function or compete for tubular transport may alter dapagliflozin exposure. Concomitant use with diuretics, certain antihypertensives, or other agents that increase urine output should be monitored to avoid excessive fluid loss.

Dosage Guidelines

Oxra 10 Mg is typically prescribed as one tablet taken orally once daily, regardless of meals. The recommended starting dose for most adults with type 2 diabetes is 10 mg, which may be titrated to 20 mg based on glycemic response and tolerability. Dose adjustment is advised for patients with moderate to severe renal impairment, as the drug’s clearance is reduced in advanced kidney disease. It is essential to follow the prescribing clinician’s instructions and to undergo regular monitoring of renal function and glycemic parameters.

If a dose is missed, the patient should take the tablet as soon as remembered unless it is nearly time for the next scheduled dose; in that case, the missed dose should be skipped and treatment should continue with the regular schedule. Overdose of Oxra 10 Mg is not typically associated with severe toxicity, but accidental ingestion of multiple tablets may increase the risk of hypoglycemia when combined with insulin or sulfonylureas and should be managed by monitoring blood glucose and seeking medical advice. Proper storage involves keeping the medication in its original packaging, protected from moisture and heat, and out of reach of children.

Side Effects

Like all medications, Oxra 10 Mg can cause adverse effects. The most commonly reported side effects include urinary tract infections, genital mycotic infections, and increased urinary frequency. These events are generally mild to moderate and often resolve with continued therapy. Less frequent but clinically important adverse reactions include hypoglycemia when the drug is used in combination with insulin or sulfonylureas, ketoacidosis, and acute kidney injury.

Patients should be advised to perform routine self‑monitoring of blood glucose and to report any persistent symptoms of urinary tract infection, genital discomfort, or signs of dehydration such as dizziness, reduced urine output, or excessive thirst. Laboratory monitoring of renal function, including periodic assessment of eGFR, is recommended at intervals determined by the prescribing clinician. Immediate medical attention is warranted if the individual experiences severe abdominal pain, nausea, vomiting, or difficulty breathing, which may indicate a serious metabolic disturbance requiring prompt evaluation.

Warnings and Precautions

Before initiating therapy with Oxra 10 Mg, clinicians should assess renal function, particularly estimated glomerular filtration rate (eGFR). The medication is not recommended for patients with an eGFR below 30 mL/min/1.73 m², as the anticipated benefit on glycemic control may be limited. Caution is also advised in individuals with a history of urinary tract infections, genital infections, or those who are prone to dehydration.

In older adults, age‑related kidney decline may require dose changes and closer monitoring. Oxra 10 Mg is not recommended during pregnancy or breastfeeding, and the safety in these groups is unproven. Women who can become pregnant should use reliable contraception while on the drug, and clinicians should discuss family‑planning options before starting therapy.

Effective control of type 2 diabetes often depends on lifestyle changes, regular lab tests, and clear communication with clinicians. When taken as prescribed, Oxra 10 Mg can add cardiovascular and kidney protection to a treatment plan. Patients should talk with their doctor about any questions or worries to ensure safe use.

Frequently Asked Questions

1. What is the typical dosing schedule for Oxra 10 Mg?

Oxra 10 Mg is taken once daily, preferably at the same time each day, with or without food. The standard starting dose is 10 mg, which may be increased to 20 mg based on the prescribing clinician’s assessment of glycemic response.

2. Can Oxra 10 Mg be used in patients with kidney disease?

Oxra 10 Mg should be used with caution in patients with moderate to severe renal impairment. Dose reduction or avoidance is recommended when the estimated glomerular filtration rate falls below 30 mL/min/1.73 m², as the drug’s efficacy and safety profile may be compromised.

3. How does Oxra 10 Mg affect blood pressure and weight?

Clinical trials have shown modest reductions in systolic blood pressure and modest weight loss in patients treated with dapagliflozin. These effects are secondary to the drug’s natriuretic and diuretic actions and may contribute to overall cardiovascular risk reduction.

4. Are there any dietary restrictions while taking Oxra 10 Mg?

No specific dietary restrictions are required. However, patients are encouraged to maintain a balanced diet and regular physical activity to optimize glycemic control and overall health. Adequate hydration is recommended to reduce the risk of dehydration.

5. Where can I find more detailed prescribing information?

Comprehensive prescribing details, including contraindications and drug interactions, are available on the official product label and can be accessed through reputable medical resources such as the U.S. Food and Drug Administration, the National Institutes of Health, or MedlinePlus.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)